- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Natasha B Leighl
J Thorac Oncol. 2017 May 09;:
Uptake of a 21-gene expression assay in breast cancer practice: views of academic and community-based oncologists.
Curr Oncol. 2017 Apr;24(2):e138-e145
Curr Oncol. 2017 Apr;24(2):103-110
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
J Clin Oncol. 2017 May 05;:JCO2016715904
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.
Oncotarget. 2017 Feb 25;:
Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.
Front Oncol. 2017;7:50
Radiother Oncol. 2017 Mar 28;:
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
Eur Respir J. 2017 Mar;49(3):
Ann Thorac Surg. 2017 Mar 03;:
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
Lung Cancer. 2017 Feb;104:65-69
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group